RNA sequencing analysis for mouse ovarian cancer cells and tumors response to B7-H3 (Cd276) depletion
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA728566 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR14479140_1.fastq.gz | Fastqsanger.gz | |||
| SRR14479140_2.fastq.gz | Fastqsanger.gz | |||
| SRR14479141_1.fastq.gz | Fastqsanger.gz | |||
| SRR14479141_2.fastq.gz | Fastqsanger.gz | |||
| SRR14479142_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 36 |
Similar Datasets
Project description:Analysis of mouse ovarian cancer cell lines HM-1 and ID8, and HM-1 tumors inoculated to B6C3F1 mice with B7-H3 (Cd276) knockout (KO) by CRISPR-Cas9. We identified B7-H3 expression is upregulated in IFN-γ–low, PD-L1–low non-immunoreactive tumors of high grade serous ovarian cancer. We explored the influence of B7-H3 on immune evasion outside of its direct regulatory function on target cells by generating B7-H3 knockout cell lines and tumors in syngeneic mouse models.
2022-01-10 | GSE174137 | GEO
Project description:Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies and cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC. Here, we aimed to develop an antibody-drug conjugate with dual payloads (DualADC) as a chemo-immunotherapy for TNBC. The overexpression of an immune checkpoint transmembrane CD276 (also known as B7-H3) was associated with angiogenesis, metastasis, and immune tolerance, in over 60% of TNBC patients. Development of a monoclonal antibody (mAb) capable of targeting the extracellular domain of surface CD276 enabled delivery of payloads to tumors, and a platform was established for concurrent conjugation of a traditional cytotoxic payload and an immunoregulating toll-like receptor 7/8 agonist to the CD276 mAb. The DualADC effectively killed multiple TNBC subtypes, significantly enhanced immune functions in the tumor microenvironment, and reduced tumor burden by up to 90-100% in animal studies. Single-cell RNA-sequencing, multiplex cytokine analysis, and histology elucidated the impact of treatment on tumor cells and the immune landscape. This study suggests that the developed DualADC could represent a promising targeted chemo-immunotherapy for TNBC.
2024-08-21 | GSE274871 | GEO
Project description:Small Cell Lung Cancer (SCLC), a highly lethal disease, limits T-cell responses by downregulating Major Histocompatibility (MHC) class I molecules. Because chimeric antigen receptor (CAR) T-cells are not MHC-restricted, they may provide a powerful strategy against SCLC. However, few CAR targets for SCLC have been identified. Here we show that B7-H3/CD276 is expressed on the surface of SCLC and thoracic SMARCA4-deficient undifferentiated tumor (UT) cells that can clinicopathologically mimic SCLC. Thoracic SMARCA4-deficient UT, despite high B7-H3 expression, limit killing by B7-H3 CAR-T cells via secretion of transforming growth factor beta 1 (TGFB1). To overcome tumor-driven CAR-T cell suppression, we knocked-in c-JUN alongside a B7-H3 CAR into the TRAC locus of primary human T-cells utilizing CRISPR/Cas9. Non-viral c-JUN+B7-H3 CAR-T cells show enhanced killing of both SCLC cells with low antigen density and thoracic SMARCA4-deficient UT, providing a platform to address these highly aggressive entities. We also provide evidence that GMP clinical scale manufacturing is feasible for c-JUN+B7-H3 CAR-T cells.
2025-11-13 | GSE307259 | GEO
Project description:Immune checkpoints are often expressed on tumor cells; it remains a prevailing need to identify the mechanisms underlying their regulation and therapeutic benefit. The immune checkpoint molecule B7-H3 is upregulated in many human tumors, including those with high mechanistic/mammalian target of rapamycin complex (mTORC1) activity. However, its role in tumor immunity and the impact of B7-H3-targeted therapy on the tumor immune microenvironment are largely uncharacterized. Here, we used a syngeneic murine model of tuberous sclerosis complex (TSC), a model of mTORC1 hyperactivity, to assess the mechanisms by which B7-H3 remodels the tumor microenvironment. We performed gene and protein expression profiling analysis using data generated from CITE-seq of infiltrating CD3+ T cells isolated by FACS from subcutaneous B7-H3 knockdown and control TSC2-deficient 105K tumors.
2023-02-08 | GSE213939 | GEO
Project description:Immune checkpoints are often expressed on tumor cells; it remains a prevailing need to identify the mechanisms underlying their regulation and therapeutic benefit. The immune checkpoint molecule B7-H3 is upregulated in many human tumors, including those with high mechanistic/mammalian target of rapamycin complex (mTORC1) activity. Still, its role in tumor immunity and the impact of B7-H3-targeted therapy on the tumor immune microenvironment are largely uncharacterized in mTORC1-hyperactive tumors. Here, we used a syngeneic murine model of tuberous sclerosis complex (TSC), a model of mTORC1 hyperactivity, to assess the mechanisms by which B7-H3 remodels the tumor microenvironment. We performed gene expression profiling analysis using data generated from RNA-seq of bulk tumors from subcutaneous B7-H3 knockdown and control TSC2-deficient 105K cells or sorted tumor cells isolated by MACS mouse tumor cell isolation kit (Miltenyi Biotec).
2023-02-08 | GSE213626 | GEO
Project description:Abstract. The use of large animal spontaneous models of solid cancers, such as dogs with osteosarcoma (OS), can help develop new cancer immunotherapy approaches, including chimeric antigen receptor (CAR) T cells. Therefore, the goal of the present study was to generate canine CAR T cells targeting the B7-H3 (CD276) co-stimulatory molecule overexpressed by several solid cancers, including OS and glioma in both humans and dogs, and to assess their ability to recognize B7-H3 expressed by canine OS cell lines or by canine tumors in xenograft models. A second objective was to determine whether a novel dual CAR that expressed a chemokine receptor together with the B7-H3 CAR improved the activity of the canine CAR T cells. Therefore, in the studies reported here we examined B7-H3 expression by canine OS tumors, evaluated target engagement by canine B7-H3 CAR T cells in vitro, and compared the relative effectiveness of B7-H3 CAR T cells versus B7-H3-CXCR2 dual CAR T cells in canine xenograft models. We found that most canine OS tumors expressed high levels of B7-H3, whereas levels were undetectable on normal dog tissues. In vitro, both B7-H3 CAR T cells demonstrated activation and OS-specific target killing in vitro, but there was significantly greater cytokine production by B7-H3-CXCR2 CAR T cells. In canine OS xenograft models, little antitumor activity was generated by B7-H3 CAR T cells, whereas B7-H3-CXCR2 CAR T cells significantly inhibited tumor growth, inducing complete tumor elimination in most treated mice. These findings indicated therefore that addition of a chemokine receptor could significantly improve the anti-tumor activity of canine B7-H3 CAR T cells, and that evaluation of this new dual CAR construct in dogs with primary or metastatic OS is warranted since such studies could provide a critical and realistic validation of the chemokine receptor concept.
2024-04-03 | GSE247355 | GEO
Project description:B7-H3 has emerged as a promising target for cancer therapy due to its high expression in various types of cancer cells. It not only regulates the activity of immune cells but also modulates the signal transduction and metabolism of cancer cells. However, the specific interaction partners of B7-H3 still remain ambiguous, limiting a comprehensive understanding of the precise role of B7-H3 in cancer progression. In this study, we reported that B7-H3 can bind to resting Raji cells, stimulated THP-1 cells, and even PC3 prostate cancer cells through its IgV domain alone. Furthermore, to identify the potential interaction partners of B7-H3 on these cells, we adopted an APEX2-based proximity labeling strategy, which unveiled about 10 key potential interaction partners. Interestingly, our results suggested that CD45 could be a putative receptor for B7-H3 on Raji cells, while EGFR could closely interact with B7-H3 on PC3 cells. Based on further computational structure modeling studies, we showed that B7-H3 can bind to the EGF binding pocket of EGFR, surprisingly stronger than EGF itself. Overall, our study provides an effective approach to identifying B7-H3 interaction partners in both immune and cancer cell lines.
2024-12-23 | PXD059197 |
Project description:mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
| PRJNA883227 | ENA
Project description:B7-H3, an immune checkpoint molecule, is overexpressed in various solid cancers, correlating with negative prognosis and poor clinical outcomes. However, its regulatory mechanisms in aggressive cancers and cancer stem cells (CSCs), which contribute to cancer formation, progression, chemoresistance, and recurrence, remain unclear. To elucidate the mechanisms regulating B7-H3 expression in breast CSCs, we employed DNA affinity purification-mass spectrometry (DAP-MS) with presumptive promoter regions of B7-H3 and identified several proteins binding to that promoter regions in CSC specific manner. Subsequent validation studies identified several potential transcription factors, including DNA damage-binding protein 1 (DDB1), XRCC5, PARP1, RPA1, and RPA3, for their significant impact on B7-H3 expression. In vitro inhibition of DDB1 with its known inhibitor, nitazoxanide, resulted in a marked decrease in B7-H3 expression, suppressing tumor sphere formation and cell migration in breast CSCs. Our findings reveal a transcription factor-mediated regulatory mechanism for B7-H3 in CSCs through proteomic analysis and highlight the critical role of these transcription factors in regulating B7-H3 expression. These results may elucidate underlying mechanisms, paving the way for the development of new immunotherapeutic strategies against breast cancer.
2025-05-07 | PXD054584 | Pride
Project description:Vδ1T cells, a rare subset of γδT cells, hold promise for treating solid tumors. Unlike conventional T cells, they recognize tumor antigens independently of the MHC antigen-presentation pathway, making them a potential “off-the-shelf” cell therapy product. However, isolation and activation of Vδ1T cells is challenging, which has limited their clinical investigation. Here, we developed a large-scale clinical-grade manufacturing process for Vδ1T cells and validated the therapeutic potential of B7-H3-CAR-modified Vδ1T cells in treating solid tumors. Co-expression of interleukin-2 with the B7-H3-CAR led to durable anti-tumor activity of Vδ1T cells in vitro and in vivo. In multiple subcutaneous and orthotopic mouse xenograft tumor models, a single intravenous administration of the CAR-Vδ1T cells resulted in complete tumor regression. These modified cells demonstrated significant in vivo expansion and robust homing ability to tumors, akin to natural tissue-resident immune cells.Additionally, the B7-H3-CAR-Vδ1T cells exhibited a favorable safety profile. In conclusion, B7-H3-CAR-modified Vδ1T cells represent a promising strategy for treating solid tumors.
2024-08-22 | GSE275242 | GEO